AU2017206041B2 - Treatments and prevention of opioid neonatal abstinence syndrome - Google Patents

Treatments and prevention of opioid neonatal abstinence syndrome Download PDF

Info

Publication number
AU2017206041B2
AU2017206041B2 AU2017206041A AU2017206041A AU2017206041B2 AU 2017206041 B2 AU2017206041 B2 AU 2017206041B2 AU 2017206041 A AU2017206041 A AU 2017206041A AU 2017206041 A AU2017206041 A AU 2017206041A AU 2017206041 B2 AU2017206041 B2 AU 2017206041B2
Authority
AU
Australia
Prior art keywords
opioid
brain
naltrexol
antagonist
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017206041A
Other languages
English (en)
Other versions
AU2017206041A1 (en
Inventor
John OBERDICK
Wolfgang Sadee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of AU2017206041A1 publication Critical patent/AU2017206041A1/en
Application granted granted Critical
Publication of AU2017206041B2 publication Critical patent/AU2017206041B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2017206041A 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome Active AU2017206041B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276691P 2016-01-08 2016-01-08
US62/276,691 2016-01-08
PCT/US2017/012452 WO2017120417A1 (en) 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome

Publications (2)

Publication Number Publication Date
AU2017206041A1 AU2017206041A1 (en) 2018-07-26
AU2017206041B2 true AU2017206041B2 (en) 2022-07-28

Family

ID=59274434

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017206041A Active AU2017206041B2 (en) 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome

Country Status (8)

Country Link
US (3) US10925870B2 (enExample)
EP (1) EP3400066B1 (enExample)
JP (1) JP7061568B2 (enExample)
CN (1) CN108778423A (enExample)
AU (1) AU2017206041B2 (enExample)
CA (1) CA3010609A1 (enExample)
DK (1) DK3400066T3 (enExample)
WO (1) WO2017120417A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066284A1 (en) * 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
CA3124115A1 (en) * 2019-01-04 2020-07-09 Aether Therapeutics Inc. Method for treating drug or alcohol dependency
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
EP4366736A4 (en) * 2021-07-06 2025-05-14 Aether Therapeutics Inc. LOW-DOSE NALTREXOL AND USES THEREOF
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069262A1 (en) * 2000-03-15 2003-04-10 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US20060240085A1 (en) * 2003-07-25 2006-10-26 Euro-Celtique S.A. Treatment of dependence withdrawal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007005790A (es) 2004-11-16 2007-09-11 Limerick Neurosciences Inc Metodos y composiciones para tratar el dolor.
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
CA2702680A1 (en) 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
US9226918B2 (en) * 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069262A1 (en) * 2000-03-15 2003-04-10 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US20060240085A1 (en) * 2003-07-25 2006-10-26 Euro-Celtique S.A. Treatment of dependence withdrawal

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Debelak, K. et al., "Buprenorphine + Naloxone in the Treatment of Opioid Dependence during Pregnancy - Initial Patient Care and Outcome Data", AM J ADDICT, 2013, vol. 22, doi:10.1111/j.1521-0391.2012.12005.x, pages 252-254 *
Farid, W. O. et al., "The Effects of Maternally Administered Methadone, Buprenorphine and Naltrexone on Offspring: Review of Human and Animal Data", CURRENT NEUROPHARMACOLOGY, 2008, vol. 6, no. 2, pages 125-150 *
NPS Medicinewise, "Buprenorphine with naloxone (Suboxone Sublingual Film) for opiate dependence", 1 September 2011, <URL: https://www.nps.org.au/radar/articles/buprenorphine-with-naloxone-suboxone-sublingual-film-for-opiate-dependence> *
Wiegand, S. L. et al., "Buprenorphine and naloxone compared with methadone treatment in pregnancy", OBSTETRICS AND GYNECOLOGY, 2015, vol. 125, no. 2, doi:10.1097/AOG.0000000000000640, pages 363-368 *

Also Published As

Publication number Publication date
US20210205296A1 (en) 2021-07-08
AU2017206041A1 (en) 2018-07-26
US12161641B2 (en) 2024-12-10
US20250177379A1 (en) 2025-06-05
EP3400066A1 (en) 2018-11-14
JP7061568B2 (ja) 2022-04-28
CA3010609A1 (en) 2017-07-13
EP3400066A4 (en) 2019-06-26
JP2019501194A (ja) 2019-01-17
CN108778423A (zh) 2018-11-09
US10925870B2 (en) 2021-02-23
US20190015406A1 (en) 2019-01-17
NZ744112A (en) 2025-05-30
EP3400066B1 (en) 2021-07-28
DK3400066T3 (da) 2021-10-18
WO2017120417A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
US20250177379A1 (en) Treatments and prevention of opioid neonatal abstinence syndrome
Jasiecka et al. Pharmacological characteristics of metamizole
AU2022221382B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
CA3208828A1 (en) Methods and compositions for treating agitation
RU2696563C9 (ru) Композиционный препарат, включающий слой пленочного покрытия, содержащий активный ингредиент
TWI483738B (zh) 具有改良之味道遮蔽性的擠出物
CN107260700A (zh) 一种替格瑞洛复方口服固体制剂的制备方法
HU211478A9 (en) Pharmaceutical composition and process for the preparation thereof
CN115811971A (zh) 用于口服施用的新型延迟释放组合物
AU2017259749B2 (en) Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
KR20200010853A (ko) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
EP3949955A1 (en) Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile
HK1260764A1 (en) Treatments and prevention of opioid neonatal abstinence syndrome
AU2006269944A2 (en) Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
US20240325379A1 (en) Low-dose naltrexol and uses thereof
PHARMACEUTICS FORMULATION AND CHARACTERIZATION OF RIZATRIPTAN BENZOATE SUBLINGUAL TABLET WITH VARIOUS PERMEATION ENHANCERS
HK40022228B (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
JPH03218323A (ja) 中枢性疾患治療剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)